DK3344626T5 - Terapeutiske forbindelser til smerte og syntese deraf - Google Patents

Terapeutiske forbindelser til smerte og syntese deraf Download PDF

Info

Publication number: DK3344626T5
Authority: DK; Denmark
Prior art keywords: pain; synthesis; therapeutic compounds; therapeutic; compounds
Prior art date: 2015-09-04

Application number

DK16842973.6T

Other languages

English (en)

Other versions

DK3344626T3 (da

Inventor

Bart Lieven Daniel Decorte

Jacob Cornelis Russcher

Menno Cornelis Franciscus Monnee

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-04

Filing date

2016-09-01

Publication date

2021-09-06

2016-09-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-07-27 Application granted granted Critical

2020-07-27 Publication of DK3344626T3 publication Critical patent/DK3344626T3/da

2021-09-06 Publication of DK3344626T5 publication Critical patent/DK3344626T5/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. ***e

DK16842973.6T 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf DK3344626T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562214727P	2015-09-04	2015-09-04
US201562214734P	2015-09-04	2015-09-04
PCT/US2016/049877 WO2017040767A1 (en)	2015-09-04	2016-09-01	Therapeutic compounds for pain and synthesis thereof

Publications (2)

Publication Number	Publication Date
DK3344626T3 DK3344626T3 (da)	2020-07-27
DK3344626T5 true DK3344626T5 (da)	2021-09-06

Family

ID=58188341

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK16842973.6T DK3344626T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842975.1T DK3344627T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842971.0T DK3344614T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842976.9T DK3344628T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser og syntese

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK16842975.1T DK3344627T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842971.0T DK3344614T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842976.9T DK3344628T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser og syntese

Country Status (11)

Country	Link
US (9)	US10040795B2 (da)
EP (5)	EP3344626B9 (da)
JP (5)	JP6736659B2 (da)
CN (5)	CN109071540B (da)
CA (5)	CA2997430C (da)
DK (4)	DK3344626T5 (da)
ES (4)	ES2807901T3 (da)
IL (5)	IL257734B (da)
MA (1)	MA45011A (da)
TW (11)	TWI663167B (da)
WO (5)	WO2017040772A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017040772A1 (en) *	2015-09-04	2017-03-09	Janssen Pharmaceutica Nv	Therapeutic compounds and synthesis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1469781A (en)	1974-06-10	1977-04-06	Boehringer Sohn Ingelheim	Production of scopine
US4232026A (en) *	1978-07-20	1980-11-04	Merck & Co., Inc.	Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) *	1984-09-06	1985-07-30	Innes Margaret N	Method of treating migraine headaches
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
EP0540526B1 (en) *	1990-07-23	1994-12-28	Pfizer Inc.	Quinuclidine derivatives
AU8906091A (en)	1990-10-05	1992-04-28	Wayne M. Barnes	Thermostable dna polymerase
DE10050994A1 (de) *	2000-10-14	2002-04-18	Boehringer Ingelheim Pharma	Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
EP1626970B1 (en) *	2003-05-28	2009-07-08	Theravance, Inc.	Azabicycloalkane compounds as muscarinic receptor antagonists
DK1678172T3 (da) *	2003-10-15	2010-04-06	Targacept Inc	Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
EP1917265B1 (en) *	2005-08-22	2010-09-29	Targacept, Inc.	HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US8735411B2 (en) *	2006-10-02	2014-05-27	Abbvie Inc.	Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) *	2007-02-28	2008-09-04	Ranbaxy Laboratories Limited	Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) *	2007-03-13	2008-10-16	Targacept Inc	Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) *	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh)	2010-01-04	2013-05-29	南昌弘益科技有限公司	噻托溴铵无水物及其制备方法
CN102579458A (zh) *	2012-03-08	2012-07-18	冀中能源峰峰集团有限公司总医院	缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) *	2012-08-24	2017-03-29	ソニー株式会社	画像処理装置および方法、並びにプログラム
AU2013319989C1 (en) *	2012-09-18	2017-08-17	Heptares Therapeutics Limited	Bicyclic aza compounds as muscarinic M1 receptor agonists
TW201444849A (zh) *	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
JO3509B1 (ar) *	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
WO2017040772A1 (en) *	2015-09-04	2017-03-09	Janssen Pharmaceutica Nv	Therapeutic compounds and synthesis

2016
- 2016-09-01 WO PCT/US2016/049885 patent/WO2017040772A1/en active Application Filing
- 2016-09-01 CN CN201680064789.4A patent/CN109071540B/zh active Active
- 2016-09-01 JP JP2018511601A patent/JP6736659B2/ja not_active Expired - Fee Related
- 2016-09-01 ES ES16842973T patent/ES2807901T3/es active Active
- 2016-09-01 EP EP16842973.6A patent/EP3344626B9/en active Active
- 2016-09-01 CA CA2997430A patent/CA2997430C/en active Active
- 2016-09-01 CN CN201680064788.XA patent/CN109153679B/zh active Active
- 2016-09-01 ES ES16842975T patent/ES2808048T3/es active Active
- 2016-09-01 EP EP16842975.1A patent/EP3344627B9/en active Active
- 2016-09-01 DK DK16842973.6T patent/DK3344626T5/da active
- 2016-09-01 US US15/254,938 patent/US10040795B2/en active Active
- 2016-09-01 DK DK16842975.1T patent/DK3344627T5/da active
- 2016-09-01 JP JP2018511607A patent/JP6736661B2/ja not_active Expired - Fee Related
- 2016-09-01 CA CA2997541A patent/CA2997541C/en active Active
- 2016-09-01 WO PCT/US2016/049871 patent/WO2017040764A1/en active Application Filing
- 2016-09-01 ES ES16842976T patent/ES2812233T3/es active Active
- 2016-09-01 DK DK16842971.0T patent/DK3344614T5/da active
- 2016-09-01 EP EP16842976.9A patent/EP3344628B9/en active Active
- 2016-09-01 EP EP16842971.0A patent/EP3344614B9/en active Active
- 2016-09-01 CA CA2997545A patent/CA2997545C/en active Active
- 2016-09-01 US US15/254,952 patent/US10040796B2/en active Active
- 2016-09-01 CA CA2997501A patent/CA2997501C/en active Active
- 2016-09-01 US US15/254,944 patent/US9994572B2/en active Active
- 2016-09-01 DK DK16842976.9T patent/DK3344628T5/da active
- 2016-09-01 CN CN201680064801.1A patent/CN108495854B/zh active Active
- 2016-09-01 WO PCT/US2016/049893 patent/WO2017040778A1/en active Application Filing
- 2016-09-01 WO PCT/US2016/049877 patent/WO2017040767A1/en active Application Filing
- 2016-09-01 US US15/254,960 patent/US10040797B2/en active Active
- 2016-09-01 EP EP16842981.9A patent/EP3344629A4/en active Pending
- 2016-09-01 WO PCT/US2016/049881 patent/WO2017040770A1/en active Application Filing
- 2016-09-01 CN CN201680064673.0A patent/CN108290890B/zh active Active
- 2016-09-01 US US15/254,965 patent/US10155762B2/en active Active
- 2016-09-01 JP JP2018511670A patent/JP6639651B2/ja active Active
- 2016-09-01 CN CN201680064790.7A patent/CN108349934B/zh active Active
- 2016-09-01 ES ES16842971T patent/ES2809703T3/es active Active
- 2016-09-01 CA CA2997543A patent/CA2997543C/en active Active
- 2016-09-01 MA MA045011A patent/MA45011A/fr unknown
- 2016-09-01 JP JP2018511626A patent/JP6868008B2/ja active Active
- 2016-09-01 JP JP2018511605A patent/JP6736660B2/ja not_active Expired - Fee Related
- 2016-09-02 TW TW105128531A patent/TWI663167B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107117875A patent/TWI686393B/zh active
- 2016-09-02 TW TW108103711A patent/TWI683815B/zh active
- 2016-09-02 TW TW105128528A patent/TWI654188B/zh active
- 2016-09-02 TW TW105128530A patent/TWI636054B/zh active
- 2016-09-02 TW TW107120678A patent/TWI707854B/zh active
- 2016-09-02 TW TW107128718A patent/TWI713879B/zh active
- 2016-09-02 TW TW105128533A patent/TWI641608B/zh active
- 2016-09-02 TW TW105128529A patent/TWI639597B/zh active
- 2016-09-02 TW TW106142501A patent/TWI695836B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107101163A patent/TWI672303B/zh active
2018
- 2018-02-26 IL IL257734A patent/IL257734B/en unknown
- 2018-02-26 IL IL257737A patent/IL257737B2/en unknown
- 2018-02-26 IL IL257740A patent/IL257740A/en active IP Right Grant
- 2018-02-26 IL IL257732A patent/IL257732B/en active IP Right Grant
- 2018-02-26 IL IL257735A patent/IL257735B/en unknown
- 2018-06-11 US US16/005,366 patent/US10351565B2/en active Active
- 2018-07-24 US US16/043,829 patent/US10358448B2/en active Active
- 2018-07-24 US US16/043,813 patent/US10351566B2/en active Active
- 2018-12-17 US US16/222,852 patent/US10766898B2/en active Active

Also Published As

Publication number	Publication date
EP3344627B9 (en)	2021-08-04
JP2018527355A (ja)	2018-09-20
ES2807901T3 (es)	2021-02-24
EP3344627B1 (en)	2020-07-01
JP6736661B2 (ja)	2020-08-05
EP3344627A4 (en)	2019-03-27
CN108495854B (zh)	2021-10-15
TWI636054B (zh)	2018-09-21
IL257740A (en)	2018-04-30
CN109071540B (zh)	2021-06-04
CN108495854A (zh)	2018-09-04
IL257737B2 (en)	2023-02-01
TW201722955A (zh)	2017-07-01
EP3344628B9 (en)	2021-06-30
DK3344627T3 (da)	2020-07-20
TWI663167B (zh)	2019-06-21
IL257737A (en)	2018-04-30
TWI654188B (zh)	2019-03-21
CA2997430C (en)	2021-05-11
WO2017040767A1 (en)	2017-03-09
DK3344627T5 (da)	2021-08-30
TW201835082A (zh)	2018-10-01
CN109071540A (zh)	2018-12-21
TWI641608B (zh)	2018-11-21
TW201722951A (zh)	2017-07-01
CA2997541A1 (en)	2017-03-09
WO2017040764A1 (en)	2017-03-09
TW201843153A (zh)	2018-12-16
CN108349934B (zh)	2021-10-22
JP2018531907A (ja)	2018-11-01
ES2807901T9 (es)	2022-01-31
JP6868008B2 (ja)	2021-05-12
EP3344627A1 (en)	2018-07-11
EP3344614B1 (en)	2020-07-08
CA2997501C (en)	2022-05-10
EP3344628B1 (en)	2020-07-15
US20170066770A1 (en)	2017-03-09
CN108290890B (zh)	2021-08-06
WO2017040770A1 (en)	2017-03-09
CN109153679A (zh)	2019-01-04
US9994572B2 (en)	2018-06-12
EP3344629A1 (en)	2018-07-11
EP3344614A1 (en)	2018-07-11
WO2017040778A1 (en)	2017-03-09
CA2997545A1 (en)	2017-03-09
US20190112311A1 (en)	2019-04-18
CA2997543A1 (en)	2017-03-09
TWI713879B (zh)	2020-12-21
TW201819381A (zh)	2018-06-01
US10040796B2 (en)	2018-08-07
DK3344628T3 (da)	2020-08-03
TW201920176A (zh)	2019-06-01
TWI639597B (zh)	2018-11-01
US20170066768A1 (en)	2017-03-09
US20170066760A1 (en)	2017-03-09
MA45011A (fr)	2021-06-02
ES2808048T3 (es)	2021-02-25
EP3344626B1 (en)	2020-07-08
JP2018527356A (ja)	2018-09-20
US20170066767A1 (en)	2017-03-09
ES2809703T9 (es)	2022-01-24
CN108349934A (zh)	2018-07-31
EP3344629A4 (en)	2019-03-27
TW201716409A (zh)	2017-05-16
EP3344626A4 (en)	2019-03-27
CA2997541C (en)	2022-01-11
US10155762B2 (en)	2018-12-18
EP3344628A4 (en)	2019-03-27
DK3344628T5 (da)	2021-07-26
CA2997543C (en)	2022-07-19
US20170066769A1 (en)	2017-03-09
JP6736660B2 (ja)	2020-08-05
IL257732B (en)	2020-11-30
IL257735A (en)	2018-04-30
US10040795B2 (en)	2018-08-07
WO2017040772A1 (en)	2017-03-09
IL257737B (en)	2022-10-01
CA2997430A1 (en)	2017-03-09
US10351565B2 (en)	2019-07-16
EP3344626B9 (en)	2021-08-11
EP3344626A1 (en)	2018-07-11
TW201811786A (zh)	2018-04-01
TWI672303B (zh)	2019-09-21
US10766898B2 (en)	2020-09-08
DK3344614T5 (da)	2021-08-30
TWI695836B (zh)	2020-06-11
JP2018526388A (ja)	2018-09-13
TW201722953A (zh)	2017-07-01
TWI707854B (zh)	2020-10-21
CA2997545C (en)	2022-01-11
ES2809703T3 (es)	2021-03-05
TW201833110A (zh)	2018-09-16
US20180291024A1 (en)	2018-10-11
TW201722954A (zh)	2017-07-01
US10351566B2 (en)	2019-07-16
EP3344628A1 (en)	2018-07-11
CA2997501A1 (en)	2017-03-09
JP6639651B2 (ja)	2020-02-05
IL257734A (en)	2018-04-30
US10358448B2 (en)	2019-07-23
IL257735B (en)	2022-01-01
ES2812233T3 (es)	2021-03-16
CN108290890A (zh)	2018-07-17
US20180327405A1 (en)	2018-11-15
CN109153679B (zh)	2022-04-08
ES2808048T9 (es)	2022-02-01
EP3344614B9 (en)	2021-07-28
ES2812233T9 (es)	2022-02-18
TWI683815B (zh)	2020-02-01
TWI686393B (zh)	2020-03-01
US10040797B2 (en)	2018-08-07
JP6736659B2 (ja)	2020-08-05
WO2017040772A9 (en)	2019-03-07
US20180327406A1 (en)	2018-11-15
EP3344614A4 (en)	2019-03-27
IL257734B (en)	2021-07-29
JP2018526387A (ja)	2018-09-13
IL257732A (en)	2018-04-30
DK3344626T3 (da)	2020-07-27
DK3344614T3 (da)	2020-07-27

Publication	Publication Date	Title
DK3294770T3 (da)	2020-12-07	Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3616720T3 (da)	2021-03-29	Farmaceutisk sammensætning til cancerbehandling
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3250237T3 (da)	2021-07-26	Hemiasterlinderivater til konjugering og terapi
DK3328880T3 (da)	2021-08-30	Terapeutiske midler
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3354282T3 (da)	2021-03-08	Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3888658T3 (da)	2024-03-18	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3698847T3 (da)	2022-01-03	Magnetisk stimuleringsudstyr til terapeutisk behandling
DK3212233T3 (da)	2020-07-27	Kombinationsterapi til behandling af sygdom
DK3183260T3 (da)	2021-06-21	Modificerede oligonukleotider og fremgangsmåder til deres syntese
DK3253382T3 (da)	2022-02-14	Farmaceutiske sammensætninger til kombinationsterapi
DK3102200T3 (da)	2023-05-22	Terapeutisk forbindelse og sammensætning
DK3265087T3 (da)	2020-10-19	Fremgangsmåde til behandling med tradipitant
DK3452475T3 (da)	2020-04-27	Tetrahydropyridodiazepinforbindelser til at behandle smerte og smerterelaterede tilstande
DK3089971T3 (da)	2020-08-31	Forbindelser og fremgangsmåder til anvendelse
DK2994157T3 (da)	2020-08-24	Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3389669T3 (da)	2023-05-01	Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3386997T3 (da)	2021-09-20	Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
DK3431460T3 (da)	2021-05-10	Ny formulering og fremgangsmåde til syntese
DK3129057T3 (da)	2023-10-02	Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
DK3445713T3 (da)	2020-05-25	Mesoporøse silicater og fremgangsmåde til syntese deraf
DK3615502T3 (da)	2023-09-25	Terapeutiske forbindelser og fremgangsmåder
DK3512544T3 (da)	2021-02-01	Peptidforbindelser og terapeutiske anvendelser deraf
DK3288965T3 (da)	2019-09-23	Opløselig kimær interleukin-10 receptor og terapeutisk anvendelse deraf